The first Phase II data for Kyorin Pharmaceutical's DPP-4 inhibitor KRP-104 show statistically significant reductions in haemoglobin A1c (HbA
) levels versus placebo when added to metformin therapy and administered either once or twice a day.
The first Phase II data for Kyorin Pharmaceutical's DPP-4 inhibitor KRP-104 show statistically significant reductions in haemoglobin A1c (HbA1c) levels versus placebo when added to metformin therapy and administered either once or twice a day.
The first Phase II data for Kyorin Pharmaceutical's DPP-4 inhibitor KRP-104 show statistically significant reductions in haemoglobin A1c (HbA
) levels versus placebo when added to metformin therapy and administered either once or twice a day.
The go-ahead to resume a trial for its only drug candidate, zetomipzomib, in hepatitis could give Kezar a glimmer of hope of reviving another halted study in lupus nephritis.
With China’s Hengrui reporting successful Phase III data for its dual GLP-1/GIP agonist, licensee Kailera is readying plans to demonstrate better efficacy than current obesity drugs.
After posting encouraging Phase II results, the company plans to meet with the US FDA about using data from an ongoing Phase III study for an accelerated approval.
Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.